OVERSEA CHINESE BANKING Corp Ltd Has $378,000 Position in Catalent, Inc. (NYSE:CTLT)

OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 18.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,242 shares of the company’s stock after buying an additional 988 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Catalent were worth $378,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of CTLT. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent in the second quarter valued at approximately $42,000. Sentry Investment Management LLC acquired a new stake in shares of Catalent in the 3rd quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC grew its stake in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares in the last quarter. Finally, Intact Investment Management Inc. bought a new stake in Catalent during the third quarter worth $73,000.

Catalent Stock Down 0.2 %

Catalent stock opened at $59.15 on Thursday. Catalent, Inc. has a twelve month low of $34.92 and a twelve month high of $61.20. The stock has a market cap of $10.74 billion, a P/E ratio of -26.17, a P/E/G ratio of 2.36 and a beta of 1.16. The company’s 50-day moving average price is $59.89 and its two-hundred day moving average price is $58.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.10) EPS. As a group, analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com upgraded Catalent from a “sell” rating to a “hold” rating in a report on Thursday. Robert W. Baird restated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Nine equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $59.83.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.